These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

876 related articles for article (PubMed ID: 34061842)

  • 1. Ivermectin as a potential treatment for COVID-19?
    Chosidow O; Bernigaud C; Guillemot D; Giraudeau B; Lespine A; Changeux JP; Bourhy H; Lecuit M; Amoura Z
    PLoS Negl Trop Dis; 2021 Jun; 15(6):e0009446. PubMed ID: 34061842
    [No Abstract]   [Full Text] [Related]  

  • 2. Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19.
    Kory P; Meduri GU; Varon J; Iglesias J; Marik PE
    Am J Ther; 2021 Apr; 28(3):e299-e318. PubMed ID: 34375047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ivermectin in dermatology: why it 'mite' be useless against COVID-19.
    Roche D; O'Connor C; Murphy M
    Clin Exp Dermatol; 2021 Oct; 46(7):1327-1328. PubMed ID: 33896010
    [No Abstract]   [Full Text] [Related]  

  • 4. A systematic review of experimental evidence for antiviral effects of ivermectin and an in silico analysis of ivermectin's possible mode of action against SARS-CoV-2.
    Kinobe RT; Owens L
    Fundam Clin Pharmacol; 2021 Apr; 35(2):260-276. PubMed ID: 33427370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Hosseini FS; Malektojari A; Ghazizadeh S; Hassaniazad M; Davoodian P; Dadvand H; Nikpoor AR; Nikoofal-Sahlabadi S; Kahoori S; Sepandi M; Hassanipour S; Fathalipour M
    Trials; 2021 Jan; 22(1):4. PubMed ID: 33397429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ivermectin: an award-winning drug with expected antiviral activity against COVID-19.
    Formiga FR; Leblanc R; de Souza Rebouças J; Farias LP; de Oliveira RN; Pena L
    J Control Release; 2021 Jan; 329():758-761. PubMed ID: 33038449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ivermectin in COVID-19: What do we know?
    Pandey S; Pathak SK; Pandey A; Salunke AA; Chawla J; Sharma A; Sharma S; Thivari P; Ratna HVK
    Diabetes Metab Syndr; 2020; 14(6):1921-1922. PubMed ID: 33032231
    [No Abstract]   [Full Text] [Related]  

  • 9. Pitfalls in Reporting Sample Size Calculation Across Randomized Controlled Trials Involving Ivermectin for the treatment of COVID-19.
    Kow CS; Hasan SS
    Am J Ther; 2021 Aug; 28(5):e616-e619. PubMed ID: 34387564
    [No Abstract]   [Full Text] [Related]  

  • 10. Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial.
    Garcia PJ; Mundaca H; Ugarte-Gil C; Leon P; Malaga G; Chaccour C; Carcamo CP
    Trials; 2021 Apr; 22(1):262. PubMed ID: 33836826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ivermectin and mortality in patients with COVID-19: A systematic review, meta-analysis, and meta-regression of randomized controlled trials.
    Zein AFMZ; Sulistiyana CS; Raffaelo WM; Pranata R
    Diabetes Metab Syndr; 2021; 15(4):102186. PubMed ID: 34237554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Need for More Randomized Controlled Trials With Rigorous Methodology to Confirm That Ivermectin Is Not a Viable Option for the Treatment of Coronavirus Disease 2019.
    Banno M; Tsujimoto Y; Ishikane M
    Clin Infect Dis; 2022 Mar; 74(6):1121-1122. PubMed ID: 34358296
    [No Abstract]   [Full Text] [Related]  

  • 13. Could the COVID-19-Driven Increased Use of Ivermectin Lead to Incidents of Imbalanced Gut Microbiota and Dysbiosis?
    Dicks LMT; Deane SM; Grobbelaar MJ
    Probiotics Antimicrob Proteins; 2022 Apr; 14(2):217-223. PubMed ID: 35218001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ivermectin as a possible treatment for COVID-19: a review of the 2022 protocols.
    Marques LLM; Beneti SC; Pinzon C; Cardoso FAR
    Braz J Biol; 2022; 84():e258325. PubMed ID: 35584459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ivermectin: An Anthelmintic, an Insecticide, and Much More.
    Martin RJ; Robertson AP; Choudhary S
    Trends Parasitol; 2021 Jan; 37(1):48-64. PubMed ID: 33189582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update to living WHO guideline on drugs for covid-19.
    BMJ; 2021 Mar; 372():n860. PubMed ID: 33789884
    [No Abstract]   [Full Text] [Related]  

  • 17. Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes.
    Kaur H; Shekhar N; Sharma S; Sarma P; Prakash A; Medhi B
    Pharmacol Rep; 2021 Jun; 73(3):736-749. PubMed ID: 33389725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ivermectin in COVID-19 Management: What is the Current Evidence?
    Eerike M; Raj GM; Priyadarshini R; Ravi G; Bisoi D; Konda VGR
    Infect Disord Drug Targets; 2022; 22(4):e190122200367. PubMed ID: 35043770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic anti-SARS-CoV-2 activity of repurposed anti-parasitic drug combinations.
    Jitobaom K; Boonarkart C; Manopwisedjaroen S; Punyadee N; Borwornpinyo S; Thitithanyanont A; Avirutnan P; Auewarakul P
    BMC Pharmacol Toxicol; 2022 Jun; 23(1):41. PubMed ID: 35717393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2.
    Jeffreys LN; Pennington SH; Duggan J; Caygill CH; Lopeman RC; Breen AF; Jinks JB; Ardrey A; Donnellan S; Patterson EI; Hughes GL; Hong DW; O'Neill PM; Aljayyoussi G; Owen A; Ward SA; Biagini GA
    Int J Antimicrob Agents; 2022 Mar; 59(3):106542. PubMed ID: 35093538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.